activator < active < actively

Facettes : Author.f AffPays.f AffRegion.f AffVille.f AffOrg.f KwdFr.f Mesh.f MeshFr.f Teeft.f

List of bibliographic references indexed by active

Number of relevant bibliographic references: 98.
[0-20] [0 - 20][0 - 50][20-40]

Ident.	Authors (with country if any)	Title
000039 (2020)	Hsien-Fu Chiu [Taïwan] ; Mei-Chin Wen [Taïwan] ; Ming-Ju Wu [Taïwan] ; Cheng-Hsu Chen [Taïwan] ; Tung-Min Yu [Taïwan] ; Ya-Wen Chuang [Taïwan] ; Shih-Ting Huang [Taïwan] ; Shang-Feng Tsai [Taïwan] ; Ying-Chih Lo [Taïwan] ; Hao-Chung Ho [Taïwan] ; Kuo-Hsiung Shu [Taïwan]	Treatment of chronic active antibody-mediated rejection in renal transplant recipients – a single center retrospective study
000143 (2020)	Eduardo Mysler [Argentine] ; Mario H. Cardiel [Mexique] ; Ricardo M. Xavier [Brésil] ; Alejandra L Pez ; Allan Ramos-Esquivel [Costa Rica]	Subcutaneous Tocilizumab in Monotherapy or in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Latin American Patients With Moderate to Severe Active Rheumatoid Arthritis: A Multicenter, Phase IIIb Study.
000166 (2020)	Elyes Bouajina [Tunisie] ; Leith Zakraoui [Tunisie] ; Montassar Kchir [Tunisie] ; Samir Kochbati [Tunisie] ; Sofiene Baklouti [Tunisie]	Safety and efficacy of tocilizumab as monotherapy or in combination with methotrexate in Tunisian patients with active rheumatoid arthritis and inadequate response to disease-modifying anti-rheumatic drugs in conditions close to clinical practice.
000410 (2020)	April A. Pottebaum ; Karthikeyan Venkatachalam [États-Unis] ; Chang Liu [États-Unis] ; Daniel C. Brennan ; Haris Murad [États-Unis] ; Andrew F. Malone [États-Unis] ; Tarek Alhamad [États-Unis]	Efficacy and Safety of Tocilizumab in the Treatment of Acute Active Antibody-mediated Rejection in Kidney Transplant Recipients
000675 (2019)	Kasia A. Sablik [Pays-Bas] ; Marian C. Clahsen-Van Groningen [Pays-Bas] ; Caspar W. N. Looman [Pays-Bas] ; Jeffrey Damman [Pays-Bas] ; Madelon Van Agteren [Pays-Bas] ; Michiel G. H. Betjes [Pays-Bas]	Treatment with intravenous immunoglobulins and methylprednisolone may significantly decrease loss of renal function in chronic-active antibody-mediated rejection
000693 (2019)	Marta Madej [Pologne] ; Patryk Woytala [Pologne] ; Marek Frankowski [Pologne] ; Łukasz Lubi Ski [Pologne] ; Renata Sokolik [Pologne] ; Agata Sebastian [Pologne] ; Beata Maci Ek-Chyra [Pologne] ; Piotr Wiland [Pologne]	Tofacitinib in the treatment of active rheumatoid arthritis – single-centre experience
000694 (2019)	Christoph Lohan [Royaume-Uni] ; Alex Diamantopoulos [Royaume-Uni] ; Corinne Lereun [France] ; Emily Wright [Royaume-Uni] ; Natalie Bohm [Royaume-Uni] ; Laura Marie Sawyer [Royaume-Uni]	Tofacitinib for the treatment of moderately to severely active ulcerative colitis: a systematic review, network meta-analysis and economic evaluation
000863 (2019)	Marie Fournier ; Chieh-I Chen [États-Unis] ; Andreas Kuznik [États-Unis] ; Clare Proudfoot [Royaume-Uni] ; Usha G. Mallya [États-Unis] ; Kaleb Michaud [États-Unis]	Sarilumab monotherapy compared with adalimumab monotherapy for the treatment of moderately to severely active rheumatoid arthritis: an analysis of incremental cost per effectively treated patient
000959 (2019)	Jacopo Mariotti ; Daniela Taurino ; Fabrizio Marino ; Stefania Bramanti ; Barbara Sarina ; Lucio Morabito ; Chiara De Philippis ; Clara Di Vito ; Domenico Mavilio ; Carmelo Carlo-Stella ; Matteo Della Porta ; Armando Santoro ; Luca Castagna	Pretransplant active disease status and HLA class II mismatching are associated with increased incidence and severity of cytokine release syndrome after haploidentical transplantation with posttransplant cyclophosphamide
000D02 (2019)	Yang-Jen Shih [Taïwan] ; Yao-Hsu Yang [Taïwan] ; Chun-Ying Lin [Taïwan] ; Chia-Ling Chang [Taïwan] ; Bor-Luen Chiang [Taïwan]	Enthesitis-related arthritis is the most common category of juvenile idiopathic arthritis in Taiwan and presents persistent active disease
000D17 (2019)	Samah Hamdy Elmedany [Égypte] ; Aly Elsayed Mohamed [Égypte] ; Sahar Mahfouz Abdel Galil [Égypte]	Efficacy and safety profile of intravenous tocilizumab versus intravenous abatacept in treating female Saudi Arabian patients with active moderate-to-severe rheumatoid arthritis.
000D20 (2019)	Han Joo Baek [Corée du Sud] ; Mie Jin Lim [Corée du Sud] ; Won Park [Corée du Sud] ; Sung Hwan Park [Corée du Sud] ; Seung-Cheol Shim [Corée du Sud] ; Dae-Hyun Yoo [Corée du Sud] ; Hyun Ah Kim [Corée du Sud] ; Soo Kon Lee [Corée du Sud] ; Yun Jong Lee [Corée du Sud] ; Young Eun Park [Corée du Sud] ; Hoon-Suk Cha [Corée du Sud] ; Yeong-Wook Song [Corée du Sud]	Efficacy and safety of tocilizumab in Korean patients with active rheumatoid arthritis.
000D49 (2019)	Noemi Muszbek [Royaume-Uni] ; Clare Proudfoot [Royaume-Uni] ; Marie Fournier [France] ; Chieh-I Chen [États-Unis] ; Andreas Kuznik [États-Unis] ; Zsofia Kiss [Royaume-Uni] ; Peter Gal [Hongrie] ; Kaleb Michaud [États-Unis]	Economic Evaluation of Sarilumab in the Treatment of Adult Patients with Moderately-to-Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs
001069 (2018-10-19)	P. Hilliquin [France] ; T. Barnetche [France] ; G. Baudens [France] ; R. Niarra [France] ; I. Idier [France] ; A. Saraux [France]	Subcutaneous Tocilizumab in Monotherapy or in Combination with DMARD in Patients with Moderate to Severe Active Rheumatoid Arthritis: Observational Study to Describe Real-World Drug Retention Rate at 12 Months, Interim Analysis
001098 (2018)	Takashi Shimizu ; Akie Kikuchi-Taura ; Soichiro Tsuji [Japon] ; Masato Matsushita [Japon] ; Shiro Ohshima ; Yukihiko Saeki	Up-regulation of CD64 Expression on Monocytes in Patients With Active Adult-Onset Still Disease: A Possible Biomarker of Disease Activity.
001107 (2018)	Sachiyo Oishi [France] ; Daniel Wendling [France] ; Jean Sibilia [France] ; Chantal Job-Deslandre [France] ; Loic Guillevin [France] ; Jacques Benichou [France] ; René Marc Flipo [France] ; Carole Duquenne [France] ; Francis Guillemin [France] ; Alain Saraux [France]	Treatment of active rheumatoid arthritis: comparison of patients younger vs older than 75 years (CORPUS cohort)
001253 (2018)	Josef S. Smolen [Autriche] ; Annette Szumski [États-Unis] ; Andrew S. Koenig [États-Unis] ; Thomas V. Jones [États-Unis] ; Lisa Marshall [États-Unis]	Predictors of remission with etanercept-methotrexate induction therapy and loss of remission with etanercept maintenance, reduction, or withdrawal in moderately active rheumatoid arthritis: results of the PRESERVE trial
001345 (2018)	I. Yokoe [Japon] ; H. Kobayashi [Japon] ; Y. Kobayashi [Japon] ; J T Giles [États-Unis] ; K. Yoneyama [Japon] ; N. Kitamura [Japon] ; M. Takei [Japon]	Impact of tocilizumab on N-terminal pro-brain natriuretic peptide levels in patients with active rheumatoid arthritis without cardiac symptoms.
001441 (2018)	Sang-Cheol Bae [Corée du Sud] ; Young Ho Lee [Corée du Sud]	Comparison of the efficacy and tolerability of tocilizumab, sarilumab, and sirukumab in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials.
001461 (2018)	Nicolino Ruperto [Italie] ; Hermine I. Brunner [États-Unis] ; Pierre Quartier [France] ; Tamàs Constantin [Hongrie] ; Nico M. Wulffraat [Pays-Bas] ; Gerd Horneff [Allemagne] ; Ozgur Kasapcopur [Turquie] ; Rayfel Schneider [Canada] ; Jordi Anton [Espagne] ; Judith Barash [Israël] ; Reinhard Berner [Allemagne] ; Fabrizia Corona [Italie] ; Ruben Cuttica [Argentine] ; Marine Fouillet-Desjonqueres [France] ; Michel Fischbach [France] ; Helen E. Foster [Royaume-Uni] ; Dirk Foell [Allemagne] ; Sebastião C. Radominski [Brésil] ; Athimalaipet V. Ramanan [Allemagne] ; Ralf Trauzeddel [Royaume-Uni] ; Erbil Unsal [Turquie] ; Jérémy Levy [Suisse] ; Eleni Vritzali [Suisse] ; Alberto Martini [Italie] ; Daniel J. Lovell [États-Unis]	Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials
001493 (2018)	Sarah Fleischer [Allemagne] ; Stefanie Ries [Allemagne] ; Ping Shen [Allemagne] ; Alix Lheritier [France] ; Frédéric Cazals [France] ; Gerd R. Burmester [Allemagne] ; Thomas Dörner [Allemagne] ; Simon Fillatreau [Allemagne]	Anti-interleukin-6 signalling therapy rebalances the disrupted cytokine production of B cells from patients with active rheumatoid arthritis.

---

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Main/Exploration

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/Title.i -k "active" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/Title.i  \
                -Sk "active" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    Title.i
   |clé=    active
}}

---

This area was generated with Dilib version V0.6.34. Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021